cb307
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2021 (NCT04839991)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFRSF9 antagonist
- Glutamate carboxypeptidase IIANTAGONIST
FOLH1 antagonist
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
- Tumor necrosis factor receptor superfamily member 9BINDING AGENT
CD137
- Serum albuminBINDING AGENT
ALB binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05836623 | Phase 1 | Dec 20, 2022 | Crescendo Bioscience, University of Groningen |
| NCT04839991 | Phase 1 | Jun 8, 2021 | Crescendo Bioscience |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crescendo Bioscience | For profit | 2 | 2 | 1 | 2021 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1